Research

Research Overview
Clinical Trials
Labs

Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page, and find specific trials by searching for a disease or condition below.

For pediatric clinical trials, visit the Ann & Robert H. Lurie Children's Hospital of Chicago website.

For more information on neuro-oncology clinical trials, visit the Robert H. Lurie Comprehensive Cancer Center of Northwestern University website.

Please contact Katarzyna Pituch, Director of Clinical Research at (312) 695-1060 or katarzyna.pituch@northwestern.edu for more information on trials.

Search Studies

Trials
Alliance A071401: Phase II Trial Of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations This phase II trial studies how well two drugs, vismodegib and GSK2256098, work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose … This phase II trial studies how well two drugs, vismodegib and GSK2256098, work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered (or mutated) genes. Altered genes can cause a tumor to grow. The study drugs, vismodegib and GSK2256098, target these genes. The study drugs could shrink the cancer, or the cancer could stay the same size or grow. They may cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one-half compared to its present size. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in meningioma patients. Eligibility Criteria You may be eligible for this research study if you have a meningioma which has gotten bigger or grew back after treatment. Principal Investigator Kumthekar, Priya U Location(s) Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT02523014IRB number STU00202953 More Info Email Study Coordinator Phone 312 695 1102 Copy Study URL to Clipboard Copy
Evoked Compound Action Potentials for Parkinson’s Disease (eCAP-PD) Study: A prospective, multicenter, single-arm feasibility study examining ECAP-controlled, closed-loop spinal cord stimulation for Parkinson’s Disease The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.… The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms. Eligibility Criteria Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease. Principal Investigator Verhagen Metman, Leonard ClinicalTrials.gov IdentifierNCT02924129IRB number STU00220312 More Info Email Jabbarinejad, Roxana Phone Copy Study URL to Clipboard Copy

Trials

Alliance A071401: Phase II Trial Of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations

This phase II trial studies how well two drugs, vismodegib and GSK2256098, work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose …

The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered (or mutated) genes. Altered genes can cause a tumor to grow. The study drugs, vismodegib and GSK2256098, target these genes. The study drugs could shrink the cancer, or the cancer could stay the same size or grow. They may cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one-half compared to its present size.

Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in meningioma patients.

Eligibility Criteria

You may be eligible for this research study if you have a meningioma which has gotten bigger or grew back after treatment.

Principal Investigator

Kumthekar, Priya U

Location(s)

Map it 201 E. Huron St.
Chicago, IL

ClinicalTrials.gov IdentifierNCT02523014IRB number STU00202953

More Info

Email Study Coordinator Phone 312 695 1102

Copy Study URL to Clipboard Copy

Evoked Compound Action Potentials for Parkinson’s Disease (eCAP-PD) Study: A prospective, multicenter, single-arm feasibility study examining ECAP-controlled, closed-loop spinal cord stimulation for Parkinson’s Disease

The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.…

The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.

Eligibility Criteria

Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease.

Principal Investigator

Verhagen Metman, Leonard

ClinicalTrials.gov IdentifierNCT02924129IRB number STU00220312

More Info

Email Jabbarinejad, Roxana Phone

Copy Study URL to Clipboard Copy